Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/281137 )
"We are very pleased to be working with Arrow" said Beactica's CEO, DrPer Kallblad. "The company has a world-class reputation for conducting breakthrough research in the antiviral field and we look forward to applying ourtechnology on their targets."
Advertisement
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beacticaprovides us with an opportunity to apply a new technology that has alreadyshown strong potential."
About Beactica
Beactica AB is a specialist drug discovery company, utilising itsproprietary methodologies to evaluate the biophysical interaction ofmolecules in order to generate novel therapeutics. As well as buildingcollaborations with external companies, Beactica is progressing its own drugdiscovery programmes.
For more information about Beactica, please visit http://www.beactica.com.
About Arrow Therapeutics
Arrow Therapeutics Ltd is a fully integrated pharmaceutical company,focused exclusively on the discovery and development of novel antiviraltherapeutics in areas of significant unmet need. Established in 1998 andacquired by AstraZeneca in February 2007, Arrow specialises in small moleculedrugs with novel mechanisms of action. The company has a number of researchand development programs, the most advanced of which target RespiratorySyncytial Virus (RSV) and Hepatitis C Virus (HCV).
For more information about Arrow Therapeutics, please visithttp://www.arrowt.co.uk.
For further information, please contact Dr Per Kallblad, CEO Beactica,+46(0)730-674488, or Dr Ken Powell, CEO Arrow Therapeutics, +44(0)207015-1000.
SOURCE Beactica AB
